Department of Neurosciences, Imaging and Clinical Sciences, Institute of Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy.
Department of Clinical Neurology, Multiple Sclerosis Centre, SS. Annunziata University Hospital, Chieti, Italy.
Diabetes Metab Res Rev. 2022 Jan;38(1):e3505. doi: 10.1002/dmrr.3505. Epub 2021 Oct 22.
Multiple sclerosis (MS) and type 1 diabetes (T1D) are chronic conditions that result from dysfunction of the immune system. Their common root in autoimmunity stimulates interest in the exploration of similarities and differences between the two diseases. Genetic susceptibility is relevant, creating a substrate, on which environmental factors act as a trigger of an aberrant immune response. Despite being both T-cell mediated disorders with a strong involvement of the humoral arm, immunomodulation is a mainstay of MS management, whereas hormone replacement therapy remains the principal approach for T1D. T1D is usually diagnosed in children and adolescents, while MS is typical of young adults. This difference has implications for disease progression and treatment. The SARS-CoV-2 pandemic and its effect on immunity may affect the prevalence of these conditions, as well as their clinical manifestation.
多发性硬化症 (MS) 和 1 型糖尿病 (T1D) 是由免疫系统功能障碍引起的慢性疾病。它们在自身免疫中的共同根源激发了人们对这两种疾病相似性和差异性的探索兴趣。遗传易感性是相关的,为环境因素作为异常免疫反应的触发因素创造了一个基质。尽管这两种疾病都是 T 细胞介导的疾病,并且体液免疫也有很强的参与,但免疫调节是 MS 治疗的主要方法,而激素替代疗法仍然是 T1D 的主要治疗方法。T1D 通常在儿童和青少年中诊断,而 MS 则是年轻人的典型疾病。这种差异对疾病的进展和治疗有影响。SARS-CoV-2 大流行及其对免疫的影响可能会影响这些疾病的流行,以及它们的临床表现。